Skip to main content

Table 3 Bivariate survival analysis: Cumulative proportion of deaths at 3 month after stroke a

From: Biomarkers of immune capacity, infection and inflammation are associated with poor outcome and mortality after stroke - the PREDICT study

Characteristic

N = 484

Death (N = 21)

Cumulative Proportion (%) of deaths (95% CI)

p-value

Overall

4.8 (2.6–7.0)

 

Sex

 

0.018

female (n = 209)

7.8 (3.7–12.0)

 

male (n = 274)

2.6 (0.4–4.8)

 

Age, yrs

 

< 0.001

 < 64 (n = 148)

2,8 (0–5,9)

 

 65–74 (n = 154)

1.6 (0–3.8)

 

 75–84 (n = 137)

6.8 (2.3–11.3)

 

 85+ (n = 45)

17.7 (5.7–29.6)

 

NIHSS

 

< 0.001

 0–4 (n = 265)

2.3 (0.3–4.3)

 

 5–15 (n = 178)

7.2 (2.9–11.3)

 

 16+ (n = 27)

22.3 (5.1–39.5)

 

Pneumonia

  

 Yes (n = 25)

28.9 (9.1–48.7)

< 0.001

 No (n = 454)

3.5 (1.5–5.5)

 

Comorbidities

 Hypertension

 

0.785

  Yes (n = 388)

5.3 (2.8–9.1)

 

  No (n = 75)

3.2 (0–7.5)

 

 Diabetes mellitus

 

0.523

  Yes (n = 128)

4.1 (0.2–8.0)

 

  No (n = 330)

5.5 (2.8–8.2)

 

 Atrial Fibrillation

 

0.013

  Yes (n = 138)

9.6 (4.1–15.1)

 

  No (n = 319)

4.6 (0.8–5.1)

 

 Hypercholesterolemia

 

0.778

  Yes (n = 237)

5.7 (2.4–9.0)

 

  No (n = 219)

4.3 (1.4–7.2)

 

 Previous stroke

 

0.276

  Yes (n = 99)

6.6 (0.9–12.3)

 

  No (n = 359)

4.6 (2.2–6.9)

 

Biomarkers

 mHLA-DR day1

 

0.014

   < =16,422 (n = 234)

7.1 (3.6–10.6)

 

   > 16,422 (n = 237)

2.6 (0.2–5.0)

 

 IL-6 day1

 

0.023

   < =4.3(n = 234)

1.6 (0–3.4)

 

   > 4.3 (n = 231)

6.2 (2.9–9.5)

 

 IL-10 day1

 

0.459

  <=5.0 (n = 387)

3.4 (1.4–5.4)

 

  >5.0 (n = 76)

6.2 (0.3–12.1)

 

 LBP day1

 

0.073

  <= 7.5 (n = 233)

1.6 (0–3.6)

 

  >7.5 (n = 231)

6.3 (2.7–9.8)

 

 TNF-α day1

 

0.216

  <=631 (n = 214)

2.1 (0–4.3)

 

  >631 (n = 244)

5.8 (2.5–9.1)

 
  1. aAnalyses were restricted to patients without missing values in the respective #cumulative Proportion of Deaths is calculated as 1- the Kaplan-Meier estimator